Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 176 participants.

Also called NCT04218552

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 176 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04218552
Other papers using this trial's data
  • Efficacy and safety of low-dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double-blind, parallel, phase II trial Journal of clinical hypertension (Greenwich, Conn.), 2022-10 DOI, PubMed 36094783, PMC9581102 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04218552. Randomized; double masking; primary purpose treatment. Start 2020-02-25 (actual); primary completion 2021-02-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension
Condition
Hypertension,Essential
Intervention (Drug)
AD209
Intervention (Drug)
Amlodipine low
Intervention (Drug)
Amlodipine high
Intervention (Drug)
Telmisartan
Lead sponsor
Addpharma Inc. (class: industry)

Record details

Record id
cardio:ct-nct04218552
Content hash
ec0102dea9f9ac4745f90d400156bfade1722e3039ee21275fe980b82821c2bb